Avalglucosidase Alfa: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Avalglucosidase Alfa. Educational only — not medical advice.
Labeled uses
NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).
Source: FDA labeling via NIH DailyMed (set 80eb3c9c…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.